1-tert-butyl 2-methyl (2S)-4-(trifluoromethanesulfonyloxy)-2,3-dihydropyrrole-1,2-dicarboxylate | 284047-10-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butyl 2-methyl (2S)-4-(trifluoromethanesulfonyloxy)-2,3-dihydropyrrole-1,2-dicarboxylate
• 英文别名: 1-O-tert-butyl 2-O-methyl (2S)-4-(trifluoromethylsulfonyloxy)-2,3-dihydropyrrole-1,2-dicarboxylate
• CAS: 284047-10-5
• 化学式: C₁₂H₁₆F₃NO₇S
• 分子量: 375.323
• InChiKey: VFXMBODOGSAEET-QMMMGPOBSA-N

物化性质

• 沸点：
  389.4±42.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  1-tert-butyl 2-methyl (2S)-4-(trifluoromethanesulfonyloxy)-2,3-dihydropyrrole-1,2-dicarboxylate 在 palladium on activated charcoal trans-benzyl(chloro)-bis(triphenylphosphine)palladium(II) 、 氢气 、 sodium carbonate 、 lithium chloride 作用下， 以 乙二醇二甲醚 、 乙酸乙酯 为溶剂， 生成 N-BOC-4(R)-phenyl-(L)-proline, methyl ester
  参考文献：
  名称：

  Synthesis and Evaluation of Some Hydroxyproline-Derived Peptidomimetics as Isoprenyltransferase Inhibitors.

  摘要：

  含有位置A2处修饰脯氨酸的CA1A2X肽模拟物被制备并评估了它们抑制法尼基转移酶（FTase）和香叶香叶基转移酶I（GGTase I）的能力，通过酶学和细胞基础检测。这些化合物在体外抑制H-ras的法尼基化，IC50值在高达数百纳摩尔至低微摩尔范围内。

  DOI：

  10.1248/cpb.48.740
• 作为产物：
  描述：

  N-Boc-反式-4-羟基-L-脯氨酸甲酯 在 草酰氯 、 二甲基亚砜 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-tert-butyl 2-methyl (2S)-4-(trifluoromethanesulfonyloxy)-2,3-dihydropyrrole-1,2-dicarboxylate
  参考文献：
  名称：

  Synthesis and Evaluation of Some Hydroxyproline-Derived Peptidomimetics as Isoprenyltransferase Inhibitors.

  摘要：

  含有位置A2处修饰脯氨酸的CA1A2X肽模拟物被制备并评估了它们抑制法尼基转移酶（FTase）和香叶香叶基转移酶I（GGTase I）的能力，通过酶学和细胞基础检测。这些化合物在体外抑制H-ras的法尼基化，IC50值在高达数百纳摩尔至低微摩尔范围内。

  DOI：

  10.1248/cpb.48.740

文献信息

• [EN] ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ARYLÉS EN TANT QUE BLOQUEURS DU CANAL POTASSIQUE SHAKER KV1.3
  申请人：DE SHAW RES LLC

  公开号：WO2021071832A1

  公开（公告）日：2021-04-15

  A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.

  描述了化合物式(I)或其药用可接受的盐，其中取代基如本文所定义。还描述了包括该化合物的药物组合物以及使用该化合物的方法。
• [EN] CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] CERTAINS INHIBITEURS DE KYNURÉNINE-3-MONO-OXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DOMINGUEZ CELIA

  公开号：WO2013016488A1

  公开（公告）日：2013-01-31

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用可接受载体的制药组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的量，以减少疾病或疾病的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化学实体作为活性剂或与一种或多种其他治疗剂结合使用至少一种化学实体。还提供了筛选具有抑制KMO活性能力的化合物的方法。
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Dominguez Celia

  公开号：US20140329816A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一个或多个药学可接受载体的制药组合物。本文描述了治疗对KMO活性抑制有反应的某些疾病和疾病的患者的方法，包括向这些患者投予至少一种化学实体的数量，以减少疾病或疾病的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿病。还描述了治疗方法，包括单独使用至少一种化学实体作为活性剂，或与一个或多个其他治疗剂联合使用至少一种化学实体。还提供了筛选能够抑制KMO活性的化合物的方法。
• US9649310B2
  申请人：——

  公开号：US9649310B2

  公开（公告）日：2017-05-16
• Synthesis and Evaluation of Some Hydroxyproline-Derived Peptidomimetics as Isoprenyltransferase Inhibitors.
  作者：Celeste E. O'CONNELL、Ceryl A. ROWELL、Karen ACKERMANN、Ana Maria GARCIA、Michael D. LEWIS、James J. KOWALCZYK

  DOI：10.1248/cpb.48.740

  日期：——

  CA1A2X peptidomimetics containing a modified proline at position A2 were prepared and evaluated for their ability to inhibit farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I) in enzymatic and cellbased assays. These compounds inhibited farnesylation of H-ras in vitro in the high nanomolar to low micromolar IC50 range.

  含有位置A2处修饰脯氨酸的CA1A2X肽模拟物被制备并评估了它们抑制法尼基转移酶（FTase）和香叶香叶基转移酶I（GGTase I）的能力，通过酶学和细胞基础检测。这些化合物在体外抑制H-ras的法尼基化，IC50值在高达数百纳摩尔至低微摩尔范围内。